Tocainide

CHEMBL1762 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

192.3 g/mol

LogP

0.8

Phase

4

Tocainide is a class Ib antiarrhythmic agent structurally related to lidocaine that blocks cardiac sodium channels in an activated/inactivated state-dependent manner, reducing the rate of rise of the action potential and shortening the effective refractory period in ventricular myocardium. It was used orally for life-threatening ventricular arrhythmias but was withdrawn from clinical use due to severe adverse effects including agranulocytosis, pulmonary fibrosis, and pulmonary edema. Unlike lidocaine, it is orally bioavailable due to its primary amine structure, but this did not outweigh its toxicity profile.

Berat Molekul

192,2600 g/mol

LogP

0,80

TPSA

55,10 Å²

Lipinski RO5

Lulus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1cccc(C)c1NC(=O)C(C)N

InChI

InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)

Molecular Formula

C11H16N2O

HBD / HBA

2 / 2

Ikatan yang Dapat Dirotasi

2

Atom Berat

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Tocainide is a class Ib antiarrhythmic agent structurally related to lidocaine that blocks cardiac sodium channels in an activated/inactivated state-dependent manner, reducing the rate of rise of the action potential and shortening the effective refractory period in ventricular myocardium. It was used orally for life-threatening ventricular arrhythmias but was withdrawn from clinical use due to severe adverse effects including agranulocytosis, pulmonary fibrosis, and pulmonary edema. Unlike lidocaine, it is orally bioavailable due to its primary amine structure, but this did …

Yes, Tocainide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1762. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 38945. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Tocainide di PillFYI

Struktur

Data Cepat

Rumus: C11H16N2O

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.